Novo Nordisk invests £1.8 bln in Danish production facility


Share post:

Hot on the heels of its popularity over weight-loss drug Wegovy, Danish drugmaker Novo Nordisk is to invest £1.8 billion to expand a production facility in Denmark for products to treat serious chronic diseases, the company said in a statement on Monday (June 12).

However, the company has clarified that the current expansion is not for the production of semaglutide, the key ingredient in Ozempic and Wegovy, which treat diabetes and weight-loss respectively.

The facility in Bagsvaerd, Denmark produces active pharmaceutical ingredient (API), the main biologically active components of medicines, and will be expanded to produce material for both current and future products.

Novo has faced major supply constraints of semaglutide after it was overwhelmed by massive demand for Wegovy during its launch in the United States in 2021, and has invested heavily to increase the supply.

Last month, the firm said it would ration the supply of starter doses for Wegovy in the U.S. to cope with demand.

Construction of the new facility is underway and it is expected to start producing API by early 2029.

“This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide,” Novo’s head of product supply, quality and IT, Henrik Wulff, said in a statement.


Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...